A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

NCT06555068 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

528

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Unresectable or Metastatic Breast Cancer

Interventions

DRUG: HRS-6209 in Combination with Fulvestrant
DRUG: HRS-6209 in Combination with HRS-1358
DRUG: HRS-6209 in Combination with Letrozole
DRUG: HRS-6209 in Combination with HRS-8080
DRUG: HRS-6209 in Combination with HRS-1358

Sponsor

Jiangsu HengRui Medicine Co., Ltd.